Ушбу ишга иқтибос қилган ишлар

3 та иш

Иш: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   МақолаCAR-T cell therapy researchClinical & Translational Oncology20261 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.000172

2. An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies

   Xin Xin, Chunhui Fan, Ran Sheng +7

   МақолаMultiple Myeloma Research and TreatmentsClinical and Experimental Medicine20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.000299

3. Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

   Amr Ali Mohamed Abdelgawwad El‐Sehrawy, Ghaleb Oriquat, Sokhib Saidov +5

   МақолаCAR-T cell therapy researchClinica Chimica Acta20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.017391